Impacts of circulating cytokine levels and gene polymorphism predisposition on type 1 diabetes mellitus

Ahmed H. Alghamdi; Sherif M. El-Sherbini; Ibrahim M. Shatla; Essam A. Mady; Mohamed F. El-Refaei

doi:10.6065/apem.2346178.089

Ann Pediatr Endocrinol Metab > Volume 29(4); 2024 > Article

Alghamdi, El-Sherbini, Shatla, Mady, and El-Refaei: Impacts of circulating cytokine levels and gene polymorphism predisposition on type 1 diabetes mellitus

Original Article

Annals of Pediatric Endocrinology & Metabolism 2024;29(4): 250-257.

Published online: August 31, 2024

DOI: https://doi.org/10.6065/apem.2346178.089

Impacts of circulating cytokine levels and gene polymorphism predisposition on type 1 diabetes mellitus

Ahmed H. Alghamdi¹

, Sherif M. El-Sherbini^2,³

, Ibrahim M. Shatla^1,⁴

, Essam A. Mady¹

, Mohamed F. El-Refaei^1,³

¹Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia

²Faculty of Science, Al-Baha University, Al-Baha, Saudi Arabia

³Genetic Institute, Sadat City University, Egypt

⁴Demietta Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Address for correspondence: Mohamed F. El-Refaei Departement of Biochemistry and Molecular Biology, Genetic Institute, Sadat City University, Sadat City, Egypt Email: melrefaei2000@yahoo.com

Received August 8, 2023 Revised February 6, 2024 Accepted April 23, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

A wide range of cytokines has been demonstrated to be involved in the etiology of type 1 diabetes mellitus (T1DM). Gene polymorphisms may potentially contribute to a hereditary predisposition toward circulating cytokine levels as (high, intermediate, or low) since they can affect cytokine production or function. The aim of this study was to investigate the roles of cytokine levels and the association of single-nucleotide polymorphisms (SNPs) within cytokine genes with T1DM in Saudi children.

Methods

Totals of 91 well-characterized T1DM patients and 91 T1DM-free control subjects were enrolled in this study.

Results

The levels of 3 circulating cytokines (transforming growth factor [TGF]-β1, interleukin [IL]-10, and IL-6) and 6 SNPs in 3 cytokine genes (TGF-β1 [rs1800470 and rs1800471], IL-10 [rs1800896, rs1800871, and rs1800872], and IL-6 [rs1800795]) that contribute to genetic susceptibility were measured by enzyme-linked immunosorbent assay and polymerase chain reaction with sequence-specific primers. Our fn dings show that TGF-β1 serum levels were signifcantly lower in the children with T1DM than in the control participants. The TGF-β1 genotypes with a high-production phenotype were signifcantly less frequent and those with a lowproduction phenotype were signifcantly more frequent in the children with T1DM compared to the control participants. respectively. Furthermore, the IL-6 genotype frequency with low level of IL-6 production were signifcantly increased in the T1DM group compared to the control group. Moreover, our data demonstrated no appreciable diferences in circulating serum level or genotype and phenotype of IL- 10 between the patients and controls.

Conclusions

This kind of measurement, which considers the prediction of T1DM, may be useful in assessing the severity of T1DM and susceptibility to T1DM among Saudi children.

Keywords: Type 1 diabetes mellitus, Single-nucleotide polymorphism, Polymerase chain reaction, Cytokines

Highlights

· Inflammation is orchestrated by cytokine in initiating and destructive stages of type 1 diabetes mellitus (T1DM).

· The low-production phenotype of transforming growth factor-β1 protect against T1DM susceptibility.

· Cytokine single-nucleotide polymorphisms have a role in regulation of autoimmune diseases, specifically T1DM.

Introduction

Type 1 diabetes mellitus (T1DM), a chronic autoimmune disease, results in a significant loss of pancreatic β-cells. Autoreactive T cells are important players in the destruction of β-cells [1]. The function and role of B cells in the humoral immune system have long been studied. B cells produce not only antibodies and an antibody-mediated memory response against pathogens, but also cell-mediated immunity. Several studies have demonstrated that B cells can activate antigenspecific CD4 and CD8 T cells, which can have cytotoxic and regulatory effects and contribute to the onset of T1DM [2]. The breakdown of the immune system is primarily mediated by T-helper 1 (Th1) cells. On the other hand, islet infiltration, immune cell activation, and other mediators contribute to the destruction of pancreatic cells and to the apparent hyperglycemia observed in this disease [3].

Exogenous insulin replacement is the current mainstay of T1DM treatment, highlighting the need for specific immunotherapy to slow disease progression and improve clinical outcomes. Genetic and immunopathogenic studies have directly linked cytokines to the pathogenesis of T1DM. Cytokines are the main cause of inflammation and are essential for controlling progressive cell degeneration [4]. The modulation of cytokine function can be a therapeutic strategy, as evidenced by studies conducted in mouse models, especially in nonobese diabetic mice, an established animal model of T1DM. Several novel cytokines have been identified as potential therapeutic targets to counteract immune-mediated cell damage [5].

Three classes of cytokines exist: those with roles that are typically anti-inflammatory (e.g., IL-10 and TGF-β1 cytokines), those with roles that are typically proinflammatory (e.g., IL-1, IL-6, and tumor necrosis factor [TNF]-α), and those that belong to the IL-12 family (e.g., IL-21 and IL-33) [6].

However, the roles of cytokines in the pathophysiology of T1DM are currently unclear and complex, especially with regard to inflammation and the course of the disease, because many dysregulated cytokines are involved in the dynamics of cytokine regulation. In the context of T1DM, very few cytokines have shown pro- or anti-inflammatory effects. For instance, in children with newly diagnosed T1DM, blocking the action of the TNF preserves β-cell function [7], and, in patients with T1DM, IL-2 treatment can increase the percentage of regulatory T-cells (Tregs) without adverse effects [8]. These findings highlight the crucial role of cytokines in the development of T1DM. The cytokine TGF-β1 has been associated with the control of innate and adaptive immunity and plays a significant role in many pathological and physiological responses [9]. Moreover, TGF-β1 secreted by Tregs plays a role in autoreactive T-cell suppression, the induction of immune tolerance, and the inhibition of proinflammatory cytokine production [10]. The signaling sequence of the TGF-β1 protein is encoded by the TGF-β1 gene polymorphisms rs1800470 and rs1800471, which impact cytokine production [11].

Several studies have suggested that Th2 (IL-4) and Th3 (IL-10 and TGF-β1) cytokines play protective roles by preventing the production of proinflammatory and Th1 cytokines [12]. As IL-10 suppresses the immune system, it is essential for immune tolerance [13]. IL-10 participates in immunological and inflammatory responses, in addition to regulating cell growth and division. This cytokine is currently regarded as an immunosuppressive agent [14] and has been connected to many autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis [15]. Moreover, IL-10 is encoded by the 3 polymorphisms rs1800896, rs1800871, and rs1800872, which impact IL-10 production.

The role of the proinflammatory cytokine IL-6 is less understood, and existing evidence is inadequate to support claims that it damages or cytotoxically affects pancreatic cells [16]. A multifunctional cytokine called IL-6 is secreted by T cells and macrophages to stimulate the immune system in cases of inflammation and infection, including the inflammatory response associated with insulin resistance. A polymorphism in the IL-6 gene (rs1800795) has been documented to exert an effect on its secretion and function [17].

The genetic contributors of T1DM among Saudis have been unexplored. The aim of the present study was to examine cytokines, their gene polymorphisms, and their correlations with predisposition for T1DM. As such, this study was conducted to elucidate and illustrate the potential roles of circulating cytokine levels of TGF-β1, IL-10, and IL-6 and 6 single-nucleotide polymorphisms (SNPs) in 3 cytokine genes (TGF-β1 [rs1800470 and rs1800471], IL-10 [rs1800896, rs1800871, and rs1800872], and IL-6 [rs1800795]) in the incidence of T1DM in Saudi children.

Materials and methods

1. Study population

A total of 182 unrelated Saudi subjects was selected and included in this study. The patient group, which consisted of 91 patients with T1DM (median age, 9 years; age range, 6–12 years), of whom 37 were male (median age, 9 years; age range, 7–12 years) and 54 were female (median age, 9 years; age range, 6–12 years), were enrolled from Al-Baha Region, Saudi Arabia. The control group included 91 unrelated healthy subjects (39 boys and 52 girls; median age, 9 years; age range, 6–12 years) free from autoimmune diseases, symptoms, and family history of T1DM. The diagnosis of T1DM was established by referring clinicians using a criterion from the American Diabetes Association— specifically, by the presence of a hemoglobin A1c level ≥6.5% (≥48 mmol/mol). Adherence to the diagnostic criterion was based on plasma glucose measured 2 hours after an oral glucose load (≥200 mg/dL [≥11.10 mmol/L]) and while fasting (≥126 mg/dL [7 mmol/L]) [18]. After recruitment, informed consent for genetic analysis was obtained from all study participants' parents before the start of the study.

2. Sample collection

Each child underwent aseptic venous blood sample collection, during which 10 mL of blood was extracted. Subsequently, collected blood samples were allowed to clot for 15 minutes. The serum was extracted through centrifugation at 1,500 rpm for 10 minutes at room temperature and was then divided into 2 sterile vacutainer tubes for immediate assessment of biochemical parameters.

3. Measurement of circulating TGF-β1, IL-10, and IL-6 levels

A second sterile vacutainer tube of serum was used to measure the levels of the selected cytokines (TGF-β1, IL-10, and IL-6). TGF-β1 was quantitatively detected in the serum by enzyme-linked immunosorbent assay (ELISA) using a human TGF-β1 ELISA kit (Invitrogen cat. no. BMS249-4; Thermo Fisher Scientific, Waltham, MA, USA). Meanwhile, an IL-10 human uncoated ELISA kit (Invitrogen cat. no. 88-7106-88; Thermo Fisher Scientific) was used to measure serum levels of IL-10, and a sandwich ELISA IL-6 human kit (Invitrogen cat no. EH2IL6; Thermo Fisher Scientific) was used to measure serum levels of IL-6. As previously mentioned, the samples were prepared and tested in duplicate in accordance with the manufacturer's instructions. The assays we used are specific for human TGF-β1, IL-10, or IL-6 and do not cross-react with other known cytokines, according to the information provided by their respective manufacturers.

4. DNA extraction

Ethylenediaminetetraacetic acid (EDTA) was added to a sterile vacutainer tube containing the venous blood sample (5 mL) from each participant. Genomic DNA was extracted from the whole-blood EDTA samples using the Gentra Puregene blood kit (Qiagen N.V., Hilden, Germany), in accordance with the manufacturer's instructions. The extracted DNA was loaded onto a 1% agarose gel to confirm its integrity. The DNA concentration was measured in each sample using the NanoDrop 2000c system (Thermo Fisher Scientific) [19].

5. Genotyping

Genomic DNA was extracted from whole blood in accordance with the manufacturer's recommendations, and the subjects' genotypes were assessed for TGF-β1 (rs1800470 and rs1800471), IL-10 (rs1800896, rs1800871, and rs1800872), and IL-6 (rs1800795) polymorphisms. Cytokine genotyping was performed with polymerase chain reaction (PCR) with sequence-specific primers using a commercial kit (One Lambda, Canoga Park, CA, USA). Based on their previously determined genotypes, study subjects were classified as low, high, or intermediate producers of the phenotypes predicted for these cytokines [20], as shown in Fig. 1A and B. PCR amplifications were performed using the PTC-200 thermal cycler (MJ Research, Inc., Waltham, MA, USA), in accordance with the manufacturer's instructions.

6. Statistical analysis

Data are summarized as follows: quantitative variables are expressed as mean±standard deviation and median with range, while frequencies are reported for categorical variables to describe the distribution of the categories within the dataset. To compare the data between the groups, an independent t-test was performed, while the chi-square and Fisher exact tests were used to compare categorical variables. A probability value (P-value) <0.05 was considered statistically significant.

7. Ethical statement

The study was conducted in accordance with ethical committee guidelines for clinical research, and ethical approval was obtained from the Ethics Committee of the Faculty of Medicine, Al-Baha University (approval no. REC/PEA/BU-FM/2023/22).

Results

1. Clinical and demographic characteristics of healthy controls and patients with T1DM

Patients with T1DM who were screened and deemed eligible were included in this study. Separately, subjects who were found to be healthy (no diabetes) during screening were recruited for the control group. Each study group consisted of 91 participants (39 boys and 52 girls in the control group and 37 boys and 54 girls in the T1DM group). Table 1 displays the study participants' baseline clinical and demographic characteristics. Compared to the healthy controls, the patients with T1DM had significantly higher mean body mass index (P<0.001) and mean creatinine, fasting glucose, postprandial blood glucose, and HbA1c levels (P < 0.001) than controls. The serum lipid profile of the patients with T1DM was significantly different from that of the controls, characterized by significantly higher total cholesterol levels and significantly lower high-density lipoprotein levels (P<0.001 for all comparisons). The patients with T1DM showed no significant difference in triglyceride level between the 2 sexes or compared to the subjects in the control group.

For the diagnosis of T1DM, a thorough examination of a cohort of 91 recently diagnosed children with diabetes was conducted, focusing on antibodies to glutamic acid decarboxylase (GAD) auto-antibodies and C-peptide levels. Among them, 69 individuals (75.8%) exhibited GAD auto-antibodies at levels above the normal reference range (38.56±4.23 IU/mL), while the remaining 22 (24.2%) showed levels within the normal range (6.72±0.84 IU/mL). Notably, 100% of individuals in this group demonstrated decreased serum C-peptide levels below the normal reference range (0.43±0.08 ng/mL). In contrast, in the control group of 91 healthy individuals, all participants exhibited levels of both GAD auto-antibodies (5.51±0.59 IU/mL) and C-peptide (2.86±0.52 ng/mL) within the normal reference range.

2. Circulating cytokine serum levels of the healthy controls and patients with T1DM

Using an ELISA kit, TGF-β1, IL-10, and IL-6 levels were quantitatively detected in serum. The patient group had a significantly lower TGF-β1 serum level than the control group (P<0.001). However, no statistically significant difference in IL-10 or IL-6 serum level was found between the control and patient groups (Table 2).

3. Cytokine genotype and production

The genotype distributions of polymorphic cytokine (TGF-β1, IL-10, and IL-6) genes were observed in T1DM patients and the T1DM-free control group. Table 3 lists the genotypes for the TGF-β1 (rs1800470 and rs1800471), IL-10 (rs1800896, rs1800871, and rs1800872), and IL-6 (rs1800795) gene polymorphisms. Serum levels of TGF-β1 in T1DM patients were significantly low compared to those in the T1DM-free group (P<0.001). On the other hand, both the serum levels of Il-10 and IL-6 showed a non-significant difference between T1DM patients and control participants. The genotypic frequencies of the cytokine genes in the T1DM and control groups are clearly illustrated in Table 3. Genotypes of cytokines TGF-β1, IL-10, and IL-6 are illustrated and categorized into 3 categories according to protein production: (A) homozygotes, corresponding to high protein production; (B) heterozygotes, corresponding to intermediate protein production; and (C) homozygotes, corresponding to low protein production [21].

The patient group exhibited significantly lower TGF-β1 production (P<0.001) than the control group. No significant changes in TGF-β1 production were observed, even though significant differences in IL-10 genotypes were found between the control and patient groups. No significant difference in the IL-6 genotype was evident between the T1DM and control subjects. Nonetheless, a significant increase in IL-6 level with a low cytokine-production phenotype was found in patients with T1DM compared to the control subjects (P<0.001).

Discussion

Diabetes is a disease with the fastest-growing global incidence rates and a linearly increasing prevalence worldwide. According to estimates from the International Diabetes Federation, more than 382 million people worldwide currently have diabetes, and this number is expected to increase to 592 million by 2035. The incidence of T1DM, which primarily affects the youth, is alarmingly increasing at a rate of 3% annually. An estimated 78,000 children younger than 14 years of age are estimated to develop T1DM each year [21].

TGF-β1 serum levels regulate important cellular functions such as the proliferation rate and production of extracellular matrix proteins in different cell types. Circulating levels of TGF-β1 might be altered in various disease states. Given the established pathophysiological role of plasma TGF-β1 level, it may be used as a target for therapeutic interventions and a prognostic indicator of the future risk of disease and/or its complications. Our findings show elevated TGF-β1 levels in the control group, consistent with the findings of Ichinose et al. [22], who suggested that high TGF-β1 levels may prevent or delay the immunosuppressive and regulatory cytokine production of many cells, including those of the Th3 and Treg subsets, possibly reducing insulin production, which is responsible for autoimmune-mediated destruction of the pancreatic islets of Langerhans [22]. This contrasts with the finding of Jakus et al. [23] who reported that TGF-β1 levels were markedly elevated in subjects with T1DM. In addition, these authors determined that serum TGF-β1 levels were significantly higher in patients with diabetes than in controls, as TGF-β1 may participate in the development and progression of diabetic microvascular and macrovascular complications.

The polymorphism (rs1800470) C/C at position +869 in the promoter region of the TGF-β1 gene is associated with higher TGF-β1 concentrations in plasma, which confirms our observation of the circulating TGF-β1 level in the control subjects. Our results also show that the polymorphism with high TGF-β1 secretion was significantly more frequent in the control subjects than in the patients with T1DM.

Moreover, our data demonstrate no appreciable differences in circulating serum level or the genotype and phenotype of IL-10 between the patients and the controls. This is in agreement with the finding of Ide et al. in a study of Japanese patients that the mean polymorphisms in the promoter region of the IL-10 gene do not correlate with a genetic predisposition to T1DM [24].

In Spanish patients with T1DM, the IL-10 genotype was assumed to have a minor influence on the risk of autoimmune diabetes [25]. Our results conflict with those of a Polish study that found a correlation between T1DM and the IL-10 (rs1800896) A/G polymorphism, especially in AA genotypes [26]. However, such differences in results may be explained by the hypothesis that these genotypes are population-specific and may cosegregate with the disease genes in different ways among ethnic groups. Our findings also differ from those of the previously published study by Gouda et al. [27], who found a significant increase in serum IL-10 level in diabetic patients compared to controls. Such results were was also confirmed by He et al., who demonstrated that elevated IL-10 levels in patients with T1DM may be due to a compensatory mechanism to increase the levels of proinflammatory cytokines [28].

Furthermore, Chen et al. [29] reported that a subgroup analysis of patient age, disease duration, and ethnicity revealed elevated IL-6 serum levels in patients with T1DM. The inflammatory cytokines from peripheral blood T lymphocytes play a vital role in the induction and development of diabetes. Recently, accumulating research has demonstrated that cytokines are associated with the inhibition of cytotoxicity in pancreatic cells [30]. Among all cytokines, IL-6 is an efficient cytokine involved in various kinds of biological activities, such as inflammatory reactions and immune responses [31]. In addition, IL-6 is a promoting cytokine that regulates insulin secretion [32]. Our study reveals no significant difference in IL-6 serum level between the control subjects and patients with T1DM, although the genetic study of the IL-6 (rs1800795) C/G SNP revealed a significant increase among subjects in the control group, who showed a low production of the IL-6 phenotype, compared to the patients with T1DM. This finding is consistent with those of studies suggesting that low IL-6 levels can induce insulin secretion, whereas high IL-6 levels inhibit insulin production [33]. Other studies have reported that the IL-6 gene may contribute to genetic susceptibility to T1DM [34]. In recent years, increasing studies have suggested that IL-6 can prevent pancreatic islet cells from experiencing apoptosis and functional lesions in vitro and in vivo [35].

Our results are in line with those of a large U.K. case-control study [36], which also found a marginally positive association between T1DM and the IL-6-174 C allele. However, our results contradict those of one of the first case-control studies on the IL-6 (rs1800795) SNP, which found that individuals who were GG-homozygous, a phenotype with low cytokine production, were more likely to develop T1DM [34]. In this investigation, those with the IL-6-174 GG genotype had lower risk of T1DM [37]. However, whether the IL-6-174 GG genotype plays a role in the pathophysiology of T1DM remains unclear, and no hard evidence suggests that it damages or even kills pancreatic cells [35]. Studies on nonobese diabetic mice, which are genetically predisposed to autoimmune diabetes, have also demonstrated that IL-6 protects against cytokine-induced cell death and functional impairment [36]. Genetic studies have shown conflicting evidence regarding the relationship between IL-6 SNPs and T1DM [38,39]. The exact mechanism through which this polymorphism influences the genetic determination of T1DM is unknown, as cytokine gene SNPs are linked to phenotypes that are both high and low producers [40]. Nevertheless, some studies have not found an association between the genotypes and the levels of cytokines secreted [38]. According to Reuss et al. [39], genetic factors account for only 50% of the observed variability in cytokine secretion; environmental factors may also have an impact. This can help explain the lack of a full understanding of how IL-6 functions in the pathophysiology of T1DM and how the rs1800795 SNP affects function.

The limitations of this study include its relatively small sample size, which impacts the generalizability of its findings. The study also focused on a specific population of Saudi children, and caution is advised when extrapolating these results to other demographics. Additionally, the exclusive examination of TGF-β1, IL-10, and IL-6 cytokines may not capture the full complexity of the immune response in T1DM. Future studies with larger, diverse cohorts exploring additional variables and broader investigations into various cytokines and immune markers are necessary for validation and extension of these findings for a more comprehensive understanding of T1DM pathogenesis.

In conclusion, cytokine networks play crucial roles in orchestrating inflammation during both the initiation and destructive phases of T1DM. The notable significant difference in TGF-β1 level that we observed greatly supports its beneficial role in inhibiting the development of T1DM. This might encourage the development of new therapeutic strategies to target TGF-β1. Our findings support the protective roles of high TGF-β1 serum levels and TGF-β1 with a low-production phenotype against susceptibility to T1DM. In Saudi children, a SNP (rs1800795) with low IL-6 production might be a preventive factor against T1DM. Our results highlight the role of cytokine SNPs in controlling autoimmune diseases, particularly T1DM, within the population under investigation. Our findings may prompt larger cohort studies to further corroborate the impacts of these SNPs on the release of these cytokines and their ensuing effects on T1DM.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study was sponsored by the Deanship of Scientific Research at Al-Baha University, Kingdom of Saudi Arabia, for financial and logistical support and for providing necessary guidance concerning project implementation (project no. 4/1440).

Data availability

The data that support the findings of this study are not publicly available but are available upon request from the corresponding author, Mohamed F. El-Refaei.

Author contribution

Conceptualization: AHA, SMES, IMS, MFER; Data curation: IMS, MFER; Formal analysis: AHA, SMES; Funding acquisition: AHA; Methodology: AHA, SMES, IMS, EAM, MFER; Project administration: AHA, SMES, IMS; Visualization: AHA, SMES, IMS, EAM, MFER; Writing - original draft: AHA, SMES, IMS, MFER; Writing - review & editing: IMS, EAM, MFER

Fig. 1.

(A, B) Two different cases demonstrates the interpretation of single-nucleotide polymorphisms for TGF-β1, IL-10, and IL-6. Gel electrophoresis for TGF-β1 (rs1800470) at codon region (+869T/C) DNA amplified band is 175bp, the amplified band means presence of T allele, TGF-β1 (rs1800471) at codon region (+915G/C) DNA amplified band is 125bp, the amplified band means presence of G allele. IL-10 (rs1800896) at promoter region (-1082 G/A) DNA amplified band is 300bp the amplified band means presence of G allele, IL-10 (rs1800871) at promoter region (-819C/T) DNA amplified band is 300bp the amplified band means presence of C allele, IL-10 (rs1800872) at promoter region (-592A/C) DNA amplified band is 250bp the amplified band means presence of A allele. IL-6 (rs1800795) at promoter region (174G/C) DNA amplified band is 175bp the amplified band means presence of G allele. TGF, transforming growth factor; IL, interleukin.

Table 1.

Clinical and demographic characteristics in healthy controls and T1DM patients

Variable	Control (n=91)	Patients (n=91)	P-value
FBG (mg/dL)	82.92±7.19	295.14±146.35	<0.001^*
PPBG (mg/dL)	113.80±8.87	387.41±134.46	<0.001^*
Creatinine (mg/dL)	0.80±0.15	1.13±0.62	<0.001^*
HbA1c (%)	5.09±0.57	8.70±1.57	<0.001^*
TC (mg/dL)	147.37±23.78	195.09±34.27	<0.001^*
TG (mg/dL)	123.80±14.80	128.04±47.04	0.44
HDL (mg/dL)	56.65±4.31	51.85±9.76	<0.001^*
BMI (kg/m²)	18.49± 1.94	21.21± 3.01	<0.001^*
Age (yr)	8.60±1.50	8.90±1.90	>0.05
Sex			0.76
Female	52 (57.14)	54 (59.34)
Male	39 (42.86)	37 (40.66)

Values are presented as mean±standard deviation or number (%).

TIDM, type 1 diabetes mellitus; FBC, fasting blood glucose; PPBG, postprandial blood glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; BMI, body mass index.

^* P<0.05, statistically significant differences.

Table 2.

Cytokines in healthy controls and T1DM patients

Variable	Control (n=91)	Patients (n=91)	P-value
TGF-β1 (pg/mL)	7.88±3.71	5.46±2.48	<0.001^*
IL-10 (pg/mL)	6.94±1.39	6.95±1.43	0.96
IL-6 (pg/mL)	9.84±2.90	9.82±3.40	0.98

Values are presented as mean±standard deviation or number (%).

TIDM, type 1 diabetes mellitus; TGF, transforming growth factor; IL, interleukin.

^* P<0.05, statistically significant differences.

Table 3.

Genotype and haplotypes frequencies of TGF-β1 (rs1800470), (rs1800471), IL-10 (rs1800896), (rs1800871), (rs1800872), and IL-6 (rs1800795) SNPs in healthy controls and T1DM patients

SNP	Genotype	Control (n=91)	Patients (n=91)	P-value
TGF-β1	C/C G/C	1 (1.1)	21 (23.08)	<0.001^*
	T/C G/C	5 (5.49)	8 (8.79)	0.39
	C/C G/G	6 (6.59)	9 (9.89)	0.42
	T/T G/C	0 (0)	3 (3.3)	0.25
	T/C G/G	79 (86.81)	27 (29.67)	<0.001^*
	T/T G/G	0 (0)	23 (25.27)	<0.001^*
TGF-β1 production	Low	1 (1.1)	21 (23.08)	<0.001^*
	Intermediate	11 (12.09)	19 (20.88)	0.11
	High	79 (86.81)	50 (54.95)	<0.001^*
IL-10	ACC/ACC	14 (15.38)	12 (13.19)	0.67
	ACC/ATA	14 (15.38)	0 (0)	<0.001^*
	ATA/ATA	0 (0)	18 (19.78)	<0.001^*
	GCC/ATA	6 (6.59)	22 (24.18)	0.001^*
	GCC/ACC	17 (18.68)	10 (10.99)	0.14
	GCC/GCC	40 (43.96)	29 (31.87)	0.09
IL-10 production	Low	28 (30.77)	30 (32.97)	0.75
	Intermediate	23 (25.27)	32 (35.16)	0.15
	High	40 (43.96)	29 (31.87)	0.09
IL-6	C/C low	6 (6.59)	25 (27.47)	<0.001^*
	G/C high	25 (27.47)	14 (15.38)	0.047^*
	G/G high	60 (65.93)	52 (57.14)	0.223
IL-6 Production	Low	6 (6.59)	25 (27.47)	<0.001^*
IL-6 Production	High	85 (93.41)	66 (72.53)

Values are presented as number (%).

SNP, single-nucleotide polymorphism; TIDM, type 1 diabetes mellitus; TGF, transforming growth factor; IL, interleukin.

^* P<0.05, statistically significant differences.

References

1. Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Role of B cells as antigen presenting cells. Front Immunol 2022;13:954936.

2. Magnuson AM, Thurber GM, Kohler RH, Weissleder R, Mathis D, Benoist C. Population dynamics of isletinfiltrating cells in autoimmune diabetes. Proc Natl Acad Sci U S A 2015;112:1511–6.

3. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018;391:2449–62.

4. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol 2013;149:279–85.

5. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871–8.

6. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244–9.

7. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013;1:295–305.

8. Dong S, Hiam-Galvez KJ, Mower y CT, Herold KC, Gitelman SE, Esensten JH, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 2021;6:e147474.

9. You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 2006;212:185–202.

10. Ninic A, Bojanin D, Sopic M, Mihajlovic M, Munjas J, Milenkovic T, et al. Transforming growth factor-beta1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2021;13:61–71.

11. Dhaouadi T, Sfar I, Bardi R, Jendoubi-Ayed S, Abdallah TB, Ayed K, et al. Cytokine gene polymorphisms in kidney transplantation. Transplant Proc 2013;45:2152–7.

12. Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J. T Helper (Th) cell profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Front Immunol 2020;11:2025.

13. Dasgupta S, Dasgupta S, Bandyopadhyay M. Regulatory B cells in infection, inflammation, and autoimmunity. Cell Immunol 2020;352:104076.

14. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity 2015;42:607–12.

15. Daien CI, Gailhac S, Mura T, Audo R, Combe B, Hahne M, et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis Rheumatol 2014;66:2037–46.

16. Yin YW, Sun QQ, Zhang BB, Hu AM, Wang Q, Liu HL, et al. The lack of association between interleukin-6 gene -174 G/C polymorphism and the risk of type 1 diabetes mellitus: a meta-analysis of 18,152 subjects. Gene 2013;515:461–5.

17. Ali YBM, El-Gahel HE, Abdel-Hakem NE, Gadalla ME, ElHefnawy MH, El-Shahat M. Association between IL-18 and IL-6 gene polymorphisms and the risk of T1D in Egyptian children. J Diabetes Metab Disord 2021;20:439–46.

18. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2016;39 Suppl 1:S13. –22. Erratum in: Diabetes Care 2016;39:1653.

19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.

20. Alper CM, Winther B, Hendley JO, Doyle WJ. Cytokine polymorphisms predict the frequency of otitis media as a complication of rhinovirus and RSV infections in children. Eur Arch Otorhinolaryngol 2009;266:199–205.

21. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.

22. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007;27:554–64.

23. Jakus V, Sapak M, Kostolanska J. Circulating TGF-beta1, glycation, and oxidation in children with diabetes mellitus type 1. Exp Diabetes Res 2012;2012:510902.

24. Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Ishii R, et al. Interleukin-10 gene promoter region polymorphisms in patients with type 1 diabetes and autoimmune thyroid disease. Ann N Y Acad Sci 2003;1005:344–7.

25. Urcelay E, Santiago JL, de la Calle H, Martinez A, Figueredo A, Fernandez-Arquero M, et al. Interleukin-10 polymorphisms in Spanish type 1 diabetes patients. Genes Immun 2004;5:306–9.

26. Siek iera U, Jarosz-Chob ot P, Janusz J, Ko eh ler B. Polimorfizm genów cytokinowych TNF-alpha (308 A/G), IL-10 (1082 A/T 819 C/T 592 A/C), IL-6 (174 C/G), IFN-gamma (874 A/T); określenie genetycznie uwarunkowanego poziomu syntezy cytokin w grupie dzieci chorych z cukrzyca typu 1 [Polymorphism of TNF-alpha (308 A/G), IL-10 (1082 A/G, 819 C/T 592 A/C), IL-6 (174 G/C), and IFN-gamma (874 A/T); genetically conditioned cytokine synthesis level in children with diabetes type 1]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2002;8:29. –34. Polish.

27. Gouda W, Mageed L, Abd El Dayem SM, Ashour E, Afify M. Evaluation of pro-inflammatory and anti-inflammatory cytokines in type 1 diabetes mellitus. Bull Natl Res Cent 2018;42:14.

28. He JS, Xie PS, Luo DS, Sun CJ, Zhang YG, Liu FX. Role of immune dysfunction in pathogenesis of type 1 diabetes mellitus in children. Asian Pac J Trop Med 2014;7:823–6.

29. Chen YL, Qiao YC, Pan YH, Xu Y, Huang YC, Wang YH, et al. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: a systematic review and meta-analysis. Cytokine 2017;94:14–20.

30. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016;893:1–19.

31. Starkie RL, Arkinstall MJ, Koukoulas I, Hawley JA, Febbraio MA. Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans. J Physiol 2001;533:585–91.

32. Sandler S, Bendtzen K, Eizirik DL, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990;126:1288–94.

33. Suzuki M, Saito M, Nagai T, Saeki H, Kazatani Y. Systemic versus coronary levels of inflammation in acute coronary syndromes. Angiology 2006;57:459–63.

34. Jahromi MM, Millward BA, Demaine AG. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J Interferon Cytokine Res 2000;20:885–8.

35. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, Park WY, et al. IL-6 protects pancreatic islet beta cells from proinflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 2004;13:43–53.

36. Cooper JD, Smyth DJ, Bailey R, Payne F, Downes K, Godfrey LM, et al. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med Genet 2007;8:71.

37. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14:109–19.

38. Cartwright NH, Keen LJ, Demaine AG, Hurlock NJ, McGonigle RJ, Rowe PA, et al. A study of cytokine gene polymorphisms and protein secretion in renal transplantation. Transpl Immunol 2001;8:237–44.

39. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors--a twin study. Genes Immun 2002;3:407–13.

40. Tayel MY, Nazir A, Abdelhamid IM, Helmy MAS, Zaki NE, Elsharkawy NS, et al. TNF-α -308 G>A and IL10 -1082A>G polymorphisms as potential risk factors for lymphoproliferative disorders in autoimmune rheumatic diseases. Egypt J Med Hum Genet 2020;21:2.